Media Coverage: CADENCE and Medera launch Asia’s first multi centre gene therapy trial for HF

CADENCE and Medera launch Asia’s first multi-centre gene therapy trial for heart failure 

Our programme, the Cardiovascular Disease National Collaborative Enterprise (CADENCE) and Medera Inc. (“Merdera”)’s Sardocor announced the initiation of a ground-breaking clinical trial for a novel gene therapy product aimed at treating heart failure (HF).

This marks the first multi-centre gene therapy trial in Asia for HF, with Singapore being the first and only site selected outside of the United States (US) for this significant translational breakthrough.

A selection of the media coverage can be accessed below: 

• BioSpectrum Asia

• Yahoo! Finance

• GlobeNewswire

• BioSpace

For more information, please refer to the following:

• Press release